Compare Stocks

2 / 10
Try these comparisons:

Stock Comparison

CGC vs CRON

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
CGC
Canopy Growth Corporation

Drug Manufacturers - Specialty & Generic

HealthcareNASDAQ • CA
Market Cap$122M
5Y Perf.-99.3%
CRON
Cronos Group Inc.

Drug Manufacturers - Specialty & Generic

HealthcareNASDAQ • CA
Market Cap$981M
5Y Perf.-60.6%

CGC vs CRON — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
CGC logoCGC
CRON logoCRON
IndustryDrug Manufacturers - Specialty & GenericDrug Manufacturers - Specialty & Generic
Market Cap$122M$981M
Revenue (TTM)$294M$193M
Net Income (TTM)$-327M$-9M
Gross Margin22.8%32.5%
Operating Margin-24.1%-1.5%
Forward P/E34.3x
Total Debt$348M$2M
Cash & Equiv.$114M$792M

CGC vs CRONLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

CGC
CRON
StockMay 20May 26Return
Canopy Growth Corpo… (CGC)1000.7-99.3%
Cronos Group Inc. (CRON)10039.4-60.6%

Price return only. Dividends and distributions are not included.

Quick Verdict: CGC vs CRON

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: CRON leads in 5 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. As sector peers, any of these can serve as alternatives in the same allocation.
CGC
Canopy Growth Corporation
The Specific-Use Pick

In this particular matchup, CGC is outpaced on most metrics by others in the set.

Best for: healthcare exposure
CRON
Cronos Group Inc.
The Income Pick

CRON carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.

  • beta 0.98
  • Rev growth 64.4%, EPS growth -100.0%, 3Y rev CAGR 30.6%
  • 14.6% 10Y total return vs CGC's -94.3%
Best for: income & stability and growth exposure
See the full category breakdown
CategoryWinnerWhy
GrowthCRON logoCRON64.4% revenue growth vs CGC's -9.5%
Quality / MarginsCRON logoCRON-4.9% margin vs CGC's -111.0%
Stability / SafetyCRON logoCRONBeta 0.98 vs CGC's 1.90, lower leverage
DividendsTieNeither stock pays a meaningful dividend
Momentum (1Y)CRON logoCRON+38.9% vs CGC's -12.4%
Efficiency (ROA)CRON logoCRON-0.8% ROA vs CGC's -29.5%, ROIC -0.8% vs -10.2%

CGC vs CRON — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

CGCCanopy Growth Corporation
FY 2024
Canadian Cannabis Net Revenue
57.9%$156M
Storz And Bickel
27.3%$73M
International And Other Revenue
14.8%$40M
Other Revenue
0.0%$0
CRONCronos Group Inc.
FY 2025
Cannabis Flower
74.0%$108M
Cannabis Extracts
25.7%$38M
Product and Service, Other
0.3%$411,000

CGC vs CRON — Financial Metrics

Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLCRONLAGGINGCGC

Income & Cash Flow (Last 12 Months)

CRON leads this category, winning 5 of 6 comparable metrics.

CGC is the larger business by revenue, generating $294M annually — 1.5x CRON's $193M. CRON is the more profitable business, keeping -4.9% of every revenue dollar as net income compared to CGC's -111.0%. On growth, CRON holds the edge at +2.0% YoY revenue growth, suggesting stronger near-term business momentum.

MetricCGC logoCGCCanopy Growth Cor…CRON logoCRONCronos Group Inc.
RevenueTrailing 12 months$294M$193M
EBITDAEarnings before interest/tax-$32M-$810,000
Net IncomeAfter-tax profit-$327M-$9M
Free Cash FlowCash after capex-$86M-$163,766
Gross MarginGross profit ÷ Revenue+22.8%+32.5%
Operating MarginEBIT ÷ Revenue-24.1%-1.5%
Net MarginNet income ÷ Revenue-111.0%-4.9%
FCF MarginFCF ÷ Revenue-29.3%-0.1%
Rev. Growth (YoY)Latest quarter vs prior year+20.9%+2.0%
EPS Growth (YoY)Latest quarter vs prior year+83.8%-100.0%
CRON leads this category, winning 5 of 6 comparable metrics.

Valuation Metrics

CGC leads this category, winning 2 of 2 comparable metrics.
MetricCGC logoCGCCanopy Growth Cor…CRON logoCRONCronos Group Inc.
Market CapShares × price$122M$981M
Enterprise ValueMkt cap + debt − cash$293M$190M
Trailing P/EPrice ÷ TTM EPS-0.28x
Forward P/EPrice ÷ next-FY EPS est.34.27x
PEG RatioP/E ÷ EPS growth rate
EV / EBITDAEnterprise value multiple
Price / SalesMarket cap ÷ Revenue0.62x5.07x
Price / BookPrice ÷ Book value/share0.34x0.90x
Price / FCFMarket cap ÷ FCF
CGC leads this category, winning 2 of 2 comparable metrics.

Profitability & Efficiency

CRON leads this category, winning 8 of 8 comparable metrics.

CRON delivers a -0.9% return on equity — every $100 of shareholder capital generates $-1 in annual profit, vs $-43 for CGC. CRON carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to CGC's 0.72x. On the Piotroski fundamental quality scale (0–9), CRON scores 6/9 vs CGC's 5/9, reflecting solid financial health.

MetricCGC logoCGCCanopy Growth Cor…CRON logoCRONCronos Group Inc.
ROE (TTM)Return on equity-43.1%-0.9%
ROA (TTM)Return on assets-29.5%-0.8%
ROICReturn on invested capital-10.2%-0.8%
ROCEReturn on capital employed-12.4%-0.3%
Piotroski ScoreFundamental quality 0–956
Debt / EquityFinancial leverage0.72x0.00x
Net DebtTotal debt minus cash$235M-$790M
Cash & Equiv.Liquid assets$114M$792M
Total DebtShort + long-term debt$348M$2M
Interest CoverageEBIT ÷ Interest expense-7.79x
CRON leads this category, winning 8 of 8 comparable metrics.

Total Returns (Dividends Reinvested)

CRON leads this category, winning 6 of 6 comparable metrics.

A $10,000 investment in CRON five years ago would be worth $3,342 today (with dividends reinvested), compared to $45 for CGC. Over the past 12 months, CRON leads with a +38.9% total return vs CGC's -12.4%. The 3-year compound annual growth rate (CAGR) favors CRON at 8.9% vs CGC's -55.9% — a key indicator of consistent wealth creation.

MetricCGC logoCGCCanopy Growth Cor…CRON logoCRONCronos Group Inc.
YTD ReturnYear-to-date-5.0%-4.8%
1-Year ReturnPast 12 months-12.4%+38.9%
3-Year ReturnCumulative with dividends-91.4%+29.1%
5-Year ReturnCumulative with dividends-99.6%-66.6%
10-Year ReturnCumulative with dividends-94.3%+1457.6%
CAGR (3Y)Annualised 3-year return-55.9%+8.9%
CRON leads this category, winning 6 of 6 comparable metrics.

Risk & Volatility

CRON leads this category, winning 2 of 2 comparable metrics.

CRON is the less volatile stock with a 0.98 beta — it tends to amplify market swings less than CGC's 1.90 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CRON currently trades 74.9% from its 52-week high vs CGC's 47.5% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricCGC logoCGCCanopy Growth Cor…CRON logoCRONCronos Group Inc.
Beta (5Y)Sensitivity to S&P 5001.90x0.98x
52-Week HighHighest price in past year$2.38$3.43
52-Week LowLowest price in past year$0.84$1.84
% of 52W HighCurrent price vs 52-week peak+47.5%+74.9%
RSI (14)Momentum oscillator 0–10052.949.3
Avg Volume (50D)Average daily shares traded10.4M1.4M
CRON leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Wall Street rates CGC as "Hold" and CRON as "Hold". Consensus price targets imply 1180.5% upside for CGC (target: $14) vs -10.5% for CRON (target: $2).

MetricCGC logoCGCCanopy Growth Cor…CRON logoCRONCronos Group Inc.
Analyst RatingConsensus buy/hold/sellHoldHold
Price TargetConsensus 12-month target$14.47$2.30
# AnalystsCovering analysts2615
Dividend YieldAnnual dividend ÷ price
Dividend StreakConsecutive years of raises
Dividend / ShareAnnual DPS
Buyback YieldShare repurchases ÷ mkt cap0.0%+1.0%
Insufficient data to determine a leader in this category.
Key Takeaway

CRON leads in 4 of 6 categories (Income & Cash Flow, Profitability & Efficiency). CGC leads in 1 (Valuation Metrics).

Best OverallCronos Group Inc. (CRON)Leads 4 of 6 categories
Loading custom metrics...

CGC vs CRON: Frequently Asked Questions

9 questions · data-driven answers · updated daily

01

Is CGC or CRON a better buy right now?

For growth investors, Cronos Group Inc.

(CRON) is the stronger pick with 64. 4% revenue growth year-over-year, versus -9. 5% for Canopy Growth Corporation (CGC). Analysts rate Canopy Growth Corporation (CGC) a "Hold" — based on 26 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which is the better long-term investment — CGC or CRON?

Over the past 5 years, Cronos Group Inc.

(CRON) delivered a total return of -66. 6%, compared to -99. 6% for Canopy Growth Corporation (CGC). Over 10 years, the gap is even starker: CRON returned +1458% versus CGC's -94. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

03

Which is safer — CGC or CRON?

By beta (market sensitivity over 5 years), Cronos Group Inc.

(CRON) is the lower-risk stock at 0. 98β versus Canopy Growth Corporation's 1. 90β — meaning CGC is approximately 93% more volatile than CRON relative to the S&P 500. On balance sheet safety, Cronos Group Inc. (CRON) carries a lower debt/equity ratio of 0% versus 72% for Canopy Growth Corporation — giving it more financial flexibility in a downturn.

04

Which is growing faster — CGC or CRON?

By revenue growth (latest reported year), Cronos Group Inc.

(CRON) is pulling ahead at 64. 4% versus -9. 5% for Canopy Growth Corporation (CGC). On earnings-per-share growth, the picture is similar: Canopy Growth Corporation grew EPS 37. 1% year-over-year, compared to -100. 0% for Cronos Group Inc.. Over a 3-year CAGR, CRON leads at 30. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

05

Which has better profit margins — CGC or CRON?

Cronos Group Inc.

(CRON) is the more profitable company, earning -4. 9% net margin versus -222. 4% for Canopy Growth Corporation — meaning it keeps -4. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CRON leads at -1. 5% versus -43. 5% for CGC. At the gross margin level — before operating expenses — CRON leads at 32. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

06

Is CGC or CRON more undervalued right now?

Analyst consensus price targets imply the most upside for CGC: 1180.

5% to $14. 47.

07

Which pays a better dividend — CGC or CRON?

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

08

Is CGC or CRON better for a retirement portfolio?

For long-horizon retirement investors, Cronos Group Inc.

(CRON) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 98), +1458% 10Y return). Canopy Growth Corporation (CGC) carries a higher beta of 1. 90 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CRON: +1458%, CGC: -94. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

09

What are the main differences between CGC and CRON?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: CGC is a small-cap quality compounder stock; CRON is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.

Stocks Like

CGC

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 10%
  • Gross Margin > 13%
Run This Screen
Stocks Like

CRON

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 100%
  • Gross Margin > 19%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform CGC and CRON on the metrics below

Revenue Growth>
%
(CGC: 20.9% · CRON: 201.3%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.